| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Potassium voltage-gated channel subfamily E member 2, MinK-related peptide 1, Minimum potassium ion channel-related peptide 1, Potassium channel subunit beta MiRP1, KCNE2 |
| Entrez GeneID | 9992 |
| WB Predicted band size | 14.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This KCNE2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 79-107 amino acids from the C-terminal region of human KCNE2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于PODXL抗体的研究文献概览：
1. **《Podocalyxin promotes invasion and metastasis in renal cell carcinoma》**
- 作者：Casey, G. 等
- 摘要：研究利用PODXL抗体通过免疫组化分析肾细胞癌组织，发现PODXL高表达与肿瘤侵袭性增强、转移风险升高及患者生存率下降相关，提示其可作为预后标志物。
2. **《Podocalyxin as a prognostic marker in colorectal cancer》**
- 作者：Sizemore, S. 等
- 摘要：通过PODXL抗体对结直肠癌样本进行染色，发现PODXL过表达与肿瘤分化程度低、淋巴结转移和总生存期缩短显著相关，支持其在临床预后评估中的价值。
3. **《Targeting podocalyxin in breast cancer metastasis》**
- 作者：Binder, Z. 等
- 摘要：研究利用抗PODXL抗体阻断乳腺癌细胞表面蛋白功能，发现其能抑制细胞迁移和体内转移，表明靶向PODXL可能成为抗转移治疗的新策略。
4. **《Podocalyxin modulates chemotherapy resistance in pancreatic cancer》**
- 作者：Hsu, Y.H. 等
- 摘要：通过Western blot和流式细胞术结合PODXL抗体，揭示PODXL通过激活PI3K/Akt通路增强胰腺癌细胞对化疗药物的耐药性，提示靶向干预可能改善疗效。
这些研究均依赖PODXL抗体进行蛋白检测或功能研究，聚焦其在癌症进展、预后和治疗中的机制与应用。
PODXL (Podocalyxin) antibodies are essential tools for studying the transmembrane glycoprotein encoded by the *PODXL* gene, which belongs to the CD34 family of cell surface sialomucins. Initially identified in kidney podocytes, podocalyxin plays a critical role in maintaining cell polarity, adhesion, and filtration function in glomerular podocytes. Beyond renal tissues, PODXL is expressed in vascular endothelial cells, hematopoietic progenitors, and certain epithelial cells, where it regulates cell morphology, migration, and anti-adhesion properties.
In cancer biology, PODXL has gained attention as an oncofetal antigen due to its overexpression in diverse malignancies, including renal, breast, colorectal, and pancreatic cancers. Elevated PODXL correlates with aggressive tumor behavior, epithelial-mesenchymal transition (EMT), metastasis, and poor prognosis, making it a potential biomarker for disease progression.
PODXL antibodies are widely used in immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to detect its expression and subcellular localization. These antibodies aid in studying PODXL's interaction with cytoskeletal proteins (e.g., ezrin, NHERF1) and its role in modulating cell signaling pathways. Therapeutic applications, such as monoclonal antibodies targeting PODXL for cancer therapy or imaging, are under exploration. However, variability in antibody specificity due to glycosylation-dependent epitopes requires careful validation in experimental models.
×
